In the current study, and compared with the NASH group, LPJZ-658 attenuated the secretion of IL-6, TNF-α, and MCP1, along with inhibiting liver IL-6, TNF-α, and IL-1β mRNA expression (Figure 3E,F). The gene discussed is CCL2; the disease is metabolic dysfunction-associated steatohepatitis.